Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.Patricia A. Pellikka, Larry K. Kvols, A. Jamil Tajik et al.|Circulation|1993Cited by 608
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.Dik J. Kwekkeboom, Eric P. Krenning, Larry K. Kvols et al.|PubMed|2005Cited by 375
Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findingsMarion de Jong, Eric P. Krenning, Roelf Valkema et al.|Seminars in Nuclear Medicine|2002Cited by 347
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.Roelf Valkema, Eric P. Krenning, Stanislas Pauwels et al.|PubMed|2005Cited by 334
Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine TumorsRoelf Valkema, Eric P. Krenning, Stanislas Pauwels et al.|Seminars in Nuclear Medicine|2006Cited by 313